Study Comparing Different MRI Contrast Agents for Detecting Liver Cancer Spread

Sponsor: University of Colorado, Denver

Sponsor score: 40
Inactive

ClinicalTrials ID:NCT04973007

Provider View

This clinical trial is testing whether a quicker MRI scan using a specific contrast agent is as effective as the standard MRI scan for finding liver cancer spread from colorectal cancer. If successful, it could save time, money, and effort for patients.

Patient Parameters

Program Overview

The study aims to find out if a faster MRI scan using a contrast agent called gadobenate dimeglumine is as good as the standard MRI scan with gadoxetate disodium in detecting liver cancer spread from colorectal cancer. This could make the process quicker and easier for patients.

Description

The main goals of this study are:

  • To compare how well a faster MRI scan using gadobenate dimeglumine detects liver cancer spread compared to other MRI scans, including the standard MRI scan with gadoxetate disodium.
  • To measure and compare the quality of images produced by the different contrast agents, focusing on how well they highlight the liver and any cancer spread.
  • To gather opinions from radiologists on which images they prefer when using the different contrast agents in the MRI scans.

Eligibility Criteria

Inclusion Criteria

  • Patients with colorectal cancer
  • Aged between 18 and 80 years
  • No previous treatments, including surgery
  • Previous imaging suggests possible liver cancer spread

Exclusion Criteria

  • Under 18 or over 80 years old
  • Poor kidney function (eGFR less than 30 ml/min/1.73 m2)
  • Previous allergic reaction to MRI contrast agents
  • Claustrophobia or movement issues that could affect scan quality
  • Implants or metal objects in the body that are not safe for MRI

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.